About: Inhaled and exhaled nitric oxide

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Inhaled and exhaled nitric oxide Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Inhaled and exhaled nitric oxide
Creator	Thébaud, B Arnal, J.-F Dinh-Xuan, A.-T Mercier, J
topic	covid:c4370d1167bde1d4b7a6e4b541c4d29dd35942e0#this
Source	PMC
abstract	Inhaled nitric oxide (NO) is used to treat various cardiopulmonary disorders associated with pulmonary hypertension. The rationale is based on the fact that NO, given by inhalation, only dilates those pulmonary vessels that perfuse well-ventilated lung units. As a result, pulmonary gas exchange is improved while pulmonary vascular resistance is reduced and pulmonary blood flow is increased. Inhaled NO has been succesfully applied to treat persistent pulmonary hypertension of the newborn, reducing the need for extracorporeal life support. Although pulmonary hypertension and altered vasoreactivity contribute to profound hypoxaemia in adult and paediatric acute respiratory distress syndrome (ARDS), the benefit of inhaled NO still remains to be established in patients with ARDS. ARDS is a complex response of the lung to direct or indirect insults, leading to pulmonary vasoconstriction and various inflammatory responses. Recent randomized trials suggest that inhaled NO only causes a transient improvement in oxygenation. Whether this effect is important in the long-term management of ARDS remains to be established. NO, measured in the exhaled breath, is an elegant and non-invasive means to monitor inflammation of the upper and lower respiratory tract. In the normal upper airways, the bulk of exhaled NO originates from the paranasal sinuses. Exhaled NO is increased in nasal allergy and decreased in cystic fibrosis, nasal polyposis and chronic sinusitis. That NO production is increased in asthmatic airways is also well established. However, several questions still need to be addressed, in particular evaluation of the sensitivity and specificity of the measurement techniques, and assessment of the bronchodilator action of endogenous NO.
has issue date	1999-01-01(xsd:dateTime)
bibo:doi	10.1007/s000180050360
bibo:pmid	10442091
has license	no-cc
sha1sum (hex)	c4370d1167bde1d4b7a6e4b541c4d29dd35942e0
schema:url	https://doi.org/10.1007/s000180050360
resource representing a document's title	Inhaled and exhaled nitric oxide
has PubMed Central identifier	PMC7096065
has PubMed identifier	10442091
schema:publication	Cell Mol Life Sci
resource representing a document's body	covid:c4370d1167bde1d4b7a6e4b541c4d29dd35942e0#body_text
is http://vocab.deri.ie/void#inDataset of	proxy:http/ns.inria.fr/covid19/c4370d1167bde1d4b7a6e4b541c4d29dd35942e0
is schema:about of	named entity 'ARDS' named entity 'nasal polyposis' named entity 'management' named entity 'monitor' named entity 'randomized trials' named entity 'PUL' named entity 'LEADING' named entity 'BULK' named entity 'EVALUATION' named entity 'MONITOR' named entity 'ASSESSMENT' named entity 'CONTRIBUTE ' named entity 'PATIENTS' named entity 'PAEDIATRIC' named entity 'SENSITIVITY AND SPECIFICITY' named entity 'LOWER RESPIRATORY TRACT' named entity 'LUNG' named entity 'IS A' named entity 'NEED' named entity 'SUGGEST' named entity 'RESULT' named entity 'VASOREACTIVITY' named entity 'APPLIED' named entity 'ASSOCIATED WITH' named entity 'ENDOGENOUS' named entity 'NASAL POLYPOSIS' named entity 'RANDOMIZED TRIALS' named entity 'CHRONIC SINUSITIS' covid:arg/c4370d1167bde1d4b7a6e4b541c4d29dd35942e0 named entity 'non-invasive' named entity 'complex' named entity 'nasal' named entity 'perfuse' named entity 'transient' named entity 'hypertension' named entity 'pulmonary gas exchange' named entity 'ARDS' named entity 'pulmonary alveoli' named entity 'nitric oxide' named entity 'nitric oxide' named entity 'ppb' named entity 'iNO' named entity 'paranasal sinus' named entity 'left heart' named entity 'viral infections' named entity 'nitric oxide' named entity 'epithelial cells' named entity 'nitric oxide' named entity 'down-regulate' named entity 'iNO' named entity 'nitric oxide' named entity 'PPHN' named entity 'Exhaled' named entity 'nitric oxide' named entity 'pulmonary hypertension' named entity 'non-specific' named entity 'nitric oxide' named entity 'biological functions' named entity 'inflammatory' named entity 'nitric oxide' named entity 'iNO' named entity 'lung function test' named entity 'PVR' named entity 'inflammatory diseases' named entity 'upper respiratory tract' named entity 'nitric oxide' named entity 'mononuclear cells' named entity 'cigarette smoke' named entity 'inflammatory cells' named entity 'eNOS' named entity 'inducible NO synthase' named entity 'nitric oxide' named entity 'iNO' named entity 'nitric oxide' named entity 'soft palate' named entity 'pulmonary artery pressure'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software